Hydrogen sulfide (H 2S) has emerged as an important gasotransmitter in the vasculature. In this study, we tested the hypothesis that H 2S contributes to coronary vasoregulation and evaluated the physiological relevance of two sources of H 2S, namely, cystathionine-␥-lyase (CSE) and 3-mercaptypyruvate sulfertransferase (MPST). MPST was detected in human coronary artery endothelial cells as well as rat and mouse coronary artery; CSE was not detected in the coronary vasculature. Rat coronary artery homogenates produced H 2S through the MPST pathway but not the CSE pathway in vitro. In vivo coronary vasorelaxation response was similar in CSE knockout mice, wild-type mice (WT), and WT mice treated with the CSE inhibitor propargylglycine, suggesting that CSE-produced H 2S does not have a significant role in coronary vasoregulation in vivo. Ex vivo, the MPST substrate 3-mercaptopyruvate (3-MP) and H 2S donor sodium hydrosulfide (NaHS) elicited similar coronary vasoreactivity responses. Pyruvate did not have any effects on vasoreactivity. The vasoactive effect of H 2S appeared to be nitric oxide (NO) dependent: H2S induced coronary vasoconstriction in the presence of NO and vasorelaxation in its absence. Maximal endothelial-dependent relaxation was intact after 3-MP and NaHS induced an increase in preconstriction tone, suggesting that endothelial NO synthase activity was not significantly inhibited. In vitro, H 2S reacted with NO, which may, in part explain the vasoconstrictive effects of 3-MP and NaHS. Taken together, these data show that MPST rather than CSE generates H 2S in coronary artery, mediating its effects through direct modulation of NO. This has important implications for H2S-based therapy in healthy and diseased coronary arteries. hydrogen sulfide; coronary vasoregulation; coronary tone; cystathionine-␥-lyase; 3-mercaptopyruvate sulfurtransferase
ing coronary blood flow. The impaired vasodilatory response of the coronary vasculature results in insufficient supply of blood and oxygen, leading to myocardial ischemia, as manifested in patients with coronary artery disease (30) . Therefore, identifying and characterizing mechanisms underlying coronary tone regulation are of clinical relevance.
Coronary tone is regulated locally by the endothelium predominantly through vasodilatory mediators nitric oxide (NO) and endothelial-derived hyperpolarizing factors (EDHFs). NO is produced by endothelial nitric oxide synthase (eNOS) and has been demonstrated to regulate resting coronary tone (11, 23) and metabolic demand-mediated vasodilation (21) . Of the EDHFs, hydrogen peroxide (H 2 O 2 ) has been the most widely researched. H 2 O 2 has similarly been shown to be involved in coronary autoregulation (27) , metabolic demand-mediated vasodilation (28) and flow-mediated vasodilation (3) .
Another EDHF, hydrogen sulfide (H 2 S), has recently emerged as another important gasotransmitter in the vasculature. H 2 S is produced from L-cysteine by cystathionine-␥-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (MPST) (22) . CSE converts L-cysteine into H 2 S with pyridoxal-5=-phosphate (PLP) as a cofactor. L-cysteine-dependent production of H 2 S by MPST is a two-step reaction. First, cysteine aminotransferase converts L-cysteine along with ␣-ketoglutarate into 3-mercaptopyruvate . MPST then converts 3-MP into H 2 S (20) . CSE appears to have an important role in vascular tone regulation as mice lacking CSE are hypertensive and have attenuated endothelial-dependent vasodilation (29) .
Vasoactive effects of H 2 S vary by vascular bed. In the mesenteric bed, H 2 S is a vasodilator (7) , while in the pulmonary bed, it is a vasoconstrictor (17) . In the aorta, the vasoactive effects of H 2 S depends on dose (14) : H 2 S is a vasoconstrictor at low doses and a vasodilator at high doses. In the coronary vasculature, H 2 S has been reported to be a vasodilator (5, 6) . Exogenous H 2 S induces coronary vasodilation independent of the endothelium through 4-aminopyridine-sensitive K v , BK Ca , and K ATP channels (4, 5, 6, 8) . The role of CSE as a producer of endogenous H 2 S has also been investigated, although conclusions regarding its contribution are inconsistent. Some studies support little contribution of CSE in coronary vasoregulation (4, 6) while others support involvement (5, 8) .
The role of MPST in coronary vasoregulation has not been examined. Moreover, the current literature on H 2 S involvement in coronary vasoregulation lacks direct measurement of H 2 S production in the coronary artery. In this study, we hypothesized that MPST is a source of endogenous H 2 S in the coronary vasculature. We measured the protein abundance of the two H 2 S-producing enzymes and measured in vitro H 2 S production through both pathways. We next investigated the role of CSE-derived H 2 S in vivo by measuring in vivo coronary vasorelaxation function in CSE inhibited and CSE knockout models. We then investigated the role of MPST-derived H 2 S by characterizing the vasoactive effects of MPST substrate 3-MP ex vivo.
MATERIALS AND METHODS
Animals. All animal use was approved by the Animal Care and Use Committee at Johns Hopkins University. In vivo coronary vasoreactivity experiments were performed in male, 12-to 18-wkold CSE-deficient (CSE Ϫ/Ϫ ) and Bl6/129S (Jackson) wild-type mice. Male 250-to 300-g Sprague-Dawley rats (Harlan) were used for ex vivo experiments.
Cell culture. Human coronary artery (HCAECs; Lonza), pulmonary artery (HPAECs; Invitrogen), and aortic endothelial cells (HAECs; Lonza) were cultured in endothelial basal medium supplemented with 5% fetal bovine serum, endothelial cell growth supplements, and penicillin/streptomycin (Lonza).
Protein expression. Protein expression was determined in human endothelial cells and rat vascular tissue by Western blot. Rat aorta and left coronary artery were harvested for analysis. Cells were lysed and tissue was homogenized in 1ϫ radioimmunoprecipitation assay (RIPA) buffer (Upstate) containing protease inhibitors (Roche). Antibodies used were rabbit-polyclonal anti-MPST antibody (1:1,000; Atlas Antibody) and rabbit-polyclonal anti-CSE antibody (1:1,000; ProteinTech). Mouse-monoclonal anti-GAPDH antibody was used as loading control (1:5,000; Novus Biologicals). Horseradish peroxidase-conjugated donkey anti-rabbit or sheep anti-mouse secondary antibody (1:5,000; GE Healthcare) was used for detection. Blots were developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Rat liver homogenates were used as positive controls.
In vitro amperometric H2S measurement. Tissue H2S production was measured by amperometry using the Apollo 4000 Free Radical Analyzer detector (WPI) and a 3-mm H2S-selective electrode (WPI). Reactions were performed as previously described (22) . For MPSTmediated H2S production, rat liver and coronary tissue samples were homogenized in cold 10ϫ PBS buffer pH 7.4 containing 1 mM dithiothrietol (DTT; New England BioLabs) and protease inhibitor (Roche). Total reaction volume was 200 l and total protein amount used was 300 g for liver and 30 g for coronary. Homogenate was incubated with MPST substrate 3-MP (Sigma) for 50 min at 37°C in 2-ml gas-tight vials (Fisher). Liver homogenate was incubated with the listed 3-MP concentrations. Coronary homogenate was incubated with 1 mM 3-MP. After 50 min of incubation, 200 l of 10ϫ PBS adjusted to pH 6.0 were added to the reaction to promote release of H2S and to stop the reaction. The reaction was incubated at 37°C for another 10 min. Two milliliters of headspace gas for liver samples and 3 ml of headspace gas for coronary samples were withdrawn from the gas-tight vial using a 10-ml syringe (BD) with a 22-G needle (BD) attached and injected into a scintillation vial containing 15 ml of 10ϫ PBS (ThermoScientific) in which the amperometric probe was equilibrating. The amount of H 2S produced by the reaction was measured by the probe in units of pA. Data were recorded 2 min after the headspace gas was injected.
For CSE-mediated H 2S production, the tissue was homogenized in 10ϫ PBS buffer containing protease inhibitor and incubated with 2 mM pyridoxal-5=-phosphate (PLP; Sigma) and L-cysteine (Sigma) (16) . Liver homogenate was incubated with listed L-cysteine concentrations. Coronary homogenate was incubated with 50 mM L-cysteine. Reaction incubation and measurement procedures were performed as described.
Experiments were performed in triplicate. H 2S produced from liver homogenate was measured as the difference in amperometric signal between the liver homogenate incubated with the indicated substrate concentration and baseline signal of the homogenate with no substrate. H 2S produced by the coronary tissue was calculated as the difference between the substrate incubated with coronary homogenate and baseline signal of the substrate incubated with no protein homogenate. A calibration curve for the amperometric probe was generated using the H 2S donor sodium hydrosulfide (NaHS) and assuming that one-third of NaHS is in soluble H 2S form (24) to equate pA units to H 2S concentration.
To examine the interaction of H 2S with NO, increasing concentrations of the no donor sodium nitroprusside (SNP) were added to NaHS (10 Ϫ3 M) and allowed to react for 1 min. Headspace gas was analyzed as above. In another set of experiments, increasing concentrations of the NO donor S-nitrosoglutathione (GSNO) were incubated with NaHS (10 Ϫ3 M) for 1 h followed by headspace sampling as above. Glutathione (GSH) was used as a control to evaluate the effects of GSNO.
In vitro fluorometric H 2S measurement. Fluorometric measurement of H 2S was performed using 7-azido-4-methylcoumarin (AzMC; Sigma). Reactions were carried out in 1ϫ PBS (Invitrogen) in a black 96-well plate with total reaction volume of 100 l. To determine NO-H2S reactivity, increasing concentration of NO donor SNP was added to 10 Ϫ3 M NaHS and allowed to react for 1 min. Fifty micromoles of AzMC were then added and incubated for 5 min at room temperature. Fluorescence intensity was measured by SpectraMax Gemini EM plate reader (Molecular Devices) at 365-nm excitation and 450-nm emission. Reactivity of AzMC to H2S was confirmed by adding 50 M AzMC to increasing NaHS concentrations, as listed.
In vivo coronary vasoreactivity. Coronary tone was evaluated in vivo by measuring coronary flow velocity using transthoracic echocardiography as previously described (26) . Mice were anesthetized with 1.5% isoflurane and coronary flow velocity was measured using the Vevo 2100 (Visual Sonics) and a 40 MHz transducer (Visual Sonics). The transducer was mounted on a stand (Visual Sonics) to measure flow velocity from the same location for the entire experiment. Chest hair was removed by depilatory cream. The animal was secured onto a heated platform to monitor ECG, heart rate, and body temperature.
The left main coronary artery was visualized by color Doppler flow from a modified long axis view of the left ventricle. Flow velocity profile of the blood flow through the coronary artery was captured by pulse wave velocity. The difference in angle between blood flow and ultrasound beam was accounted for with angle correction done on the Vevo mainframe.
Coronary vasorelaxation was induced by intravenous transfusion of adenosine triphosphate (ATP; Sigma) or the ␤-adrenergic agonist dobutamine (Dob; Hospira). ATP was administered to evaluate agonist-induced coronary vasorelaxation and dobutamine to evaluate metabolic demand-mediated vasorelaxation. Increase in diameter corresponded with an increase in flow velocity. Drugs were infused through a catheter inserted into the lateral tail vein. Catheters were custom-made by attaching a 30-G needle (BD) to size PE-10 polyethylene tubing (BD). The dose of drug administered was controlled with a syringe pump (Harvard Apparatus) by adjusting infusion rate.
Working concentration of ATP was 0.5 mg/ml. ATP was infused at 20, 40, 80, and 160 g·kg Ϫ1 ·min Ϫ1 for 1 min/dose. Coronary flow velocity was allowed to return to baseline between each dose. Working concentration of dobutamine was 0.2 mg/ml. Dobutamine was infused at 5, 10, 20, and 30 g·kg Ϫ1 ·min Ϫ1 at 2 min per dose. The CSE inhibitor propargylglycine (PPG; Sigma) dissolved in saline was administered intravenously at 50 mg/kg 30 min before flow velocity measurements. All drugs were prepared in a heparinized 0.9% saline solution. Peak diastolic flow velocities of three cardiac cycles were measured for data analysis.
Wire myography. Rats were euthanized by isoflurane overdose, and the left main and descending coronary artery was dissected and sectioned into ϳ1-mm rings. Precise vessel section length was measured and vessel sections were mounted onto a wire myograph (DMT). Vessels were bathed in 95%-5% O2-CO2 oxygenated Krebs physiological solution containing the following (in mM): 118 NaCl, 4.7 KCl, 25.0 NaHCO3, 1.2 MgSO4, 1.1 KH2PO4, 11 glucose, and 2.5 CaCl 2-2H2O maintained at 37°C. Vessels were equilibrated for 30 min and then stretched in 0.3-mN increments to the tension equivalent to 50 mmHg (6.7 kPa), as determined by the DMT normalization module for LabChart. After being stretched, vessels were equilibrated for 15 min, and then subjected to two rounds of 60 mM KCl bolus administration into the bath. Vessels were preconstricted at 10 Ϫ7 M or 10 Ϫ6.5 M U46619 (Cayman) for 15 min. Vessels were then subjected to cumulative dose response of NaHS (10 Ϫ5 M, 10 Ϫ4 M, and 10 Ϫ3 M; Sigma) or 3-MP (10 Ϫ6 M, 10 Ϫ5 M, 10 Ϫ4 M; Sigma). To test the involvement of arachidonic acid, rings were next incubated with 10 M phospholipase A2 inhibitor 4-4(-octadecylphenyl)-4-oxobutenoic acid (OBAA; Tocris) for 30 min prior to U46619 preconstriction, and NaHS and 3-MP dose responses were carried out. Rings were then incubated with 100 M N G -nitro-L-arginine methyl ester (L-NAME; Caymen) for 15 min before U46619 preconstriction to test the involvement of NOS-dependent NO. In a separate experiment, coronary artery rings were mechanically denuded to examine the role of the endothelium in the H2S-and 3-MP-mediated response.
Acetylcholine (ACh; Sigma) 10 Ϫ5 M was added after NaHS 10
Ϫ3
M and 3-MP 10 Ϫ4 M to determine if endothelial-mediated vasorelaxation function remained intact. In separate challenges, vessels were preconstricted with U46619, and after steady constriction was reached, 100 M L-NAME were added. After a steady L-NAMEinduced constriction was reached, ACh 10 Ϫ5 M was added to evaluate endothelial-mediated vasorelaxation after NOS inhibition.
Data analysis and statistics. Statistical significance was determined by two-way analysis of variance with Bonferroni posttest or Student's t-test (GraphPad). Data are reported as means Ϯ SE.
RESULTS

CSE and MPST expression in cells and tissue.
CSE expression varied between human endothelial cell lines: expression was robust in HAECs and HPAECs and minimal in HCAECs in comparison (Fig. 1A) . MPST and eNOS abundances were in similar in all the cell types. Rat liver was used as a positive control.
In rats (Fig. 1B) MPST was expressed in similar abundance in coronary artery and aorta. In mice, MPST expression was more robust in the coronary artery compared with the aorta (Fig. 1C) . CSE expression was more robust in aortic tissue in both rats and mice compared with the coronary artery (Fig. 1,  B and C) . GAPDH was used as the loading control.
MPST-and CSE-mediated H 2 S production in tissue and cells. Enzymatic kinetics of MPST and CSE were characterized in rat liver homogenate, where both enzymes are robustly expressed (Fig. 1A) (10, 19) . The K m value of MPST for 3-MP in the reaction conditions was 0.46 Ϯ 0.08 mM 3-MP and V max was 254.1 Ϯ 9.6 nM H 2 S/h ( Fig. 2A) . For the CSE reaction with L-cysteine as substrate, K m was 21.38 Ϯ 4.31 mM L-cysteine, and V max was 1,777 nM H 2 S/h (Fig. 2B) .
To measure enzyme activity, the coronary artery homogenate was incubated with 1 mM 3-MP or 50 mM L-cysteine. H 2 S produced in these conditions was 32.4 Ϯ 6.1 nM for 3-MP incubation and 3.6 Ϯ 6.5 nM for L-cysteine incubation. MPSTmediated production was significantly higher than CSE-mediated production ( Fig. 2C ; P ϭ 0.0056).
Similarly, in HCAECs, 3-MPST-dependent H 2 S production (1.38 Ϯ 0.12 nM) was significantly higher than CSE-mediated production (0.25 Ϯ 0.1 nM; P ϭ 0.0017; Fig. 2D) . (Fig. 3A) was not different among WT, WT treated with PPG, and CSE Ϫ/Ϫ mice (P ϭ 0.33 for WT vs. PPG treated and P ϭ 0.31 for WT vs. CSE
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Ϫ/Ϫ
). Metabolic demand-mediated vasorelaxation induced by dobutamine (Fig. 3B ) was also not different between cohorts (P ϭ 0.66 for WT vs. PPG-treated and P ϭ 0.23 for WT vs. CSE
).
Vasoactive effects of exogenous H 2 S and 3-MP. 3-MP caused dose-dependent vasoconstriction in coronary rings (Fig. 4A): 10
Ϫ6 M decreased preconstriction tone by 3.6 Ϯ 2.2% while 10 Ϫ5 M significantly increased preconstriction tone by 19.7 Ϯ 9.5% (P ϭ 0.022 compared with 3-MP 10 Ϫ6 M), and 10 Ϫ4 M increased preconstriction tone by 68.6 Ϯ 26%. (P ϭ 0.059 compared with 3-MP 10 Ϫ5 M). Pyruvate did not have any effects on vasoconstriction (Fig. 5E) . The vasoconstrictive response to 3-MP was not significantly altered following incubation with the PLA2 inhibitor OBAA (P ϭ 0.29 OBAA vs. untreated) but was dramatically reduced following NOS inhibition with L-NAME. A dose of 10 Ϫ4 M 3-MP produced an 8.2 Ϯ 4.3% increase in preconstriction tone with L-NAME incubation compared with 68.6 Ϯ 26.2% increase in tone in untreated vessels (P ϭ 0.026). Removal of the endothelium similarly abolished vasoconstrictive effect of 3-MP and unmasked its vasodilatory effect: 10 Ϫ4 M produced a 7.9 Ϯ 6.5% decrease in tone in denuded vessels compared with the 68.6 Ϯ 26% increase in tone in endothelial-intact vessels (P ϭ 0.034). NaHS induced a dose-dependent vasoconstriction in the coronary arteries (Fig. 4B) : a 4.9 Ϯ 3.7% increase in preconstriction tone occurred with 10 Ϫ5 M, 18.3 Ϯ 4.7% increase occurred with 10 Ϫ4 M (P ϭ 0.029 vs. 10 Ϫ5 M), and 218.5 Ϯ 52.0% occurred with 10 Ϫ3 M (P ϭ 0.0025 vs. NaHS 10 Ϫ4 M). Following PLA2 inhibition with OBAA, NaHS also produced dose-dependent vasoconstriction but to a lesser degree: 10 Ϫ5 M produced a 95.9 Ϯ 30.9% increase in preconstriction tone with OBAA incubation compared with 218.0 Ϯ 52.0% increase in preconstriction tone in untreated vessels (P ϭ 0.039). Following L-NAME incubation, NaHS induced dose-dependent vasodilation: 10 Ϫ5 M NaHS increased preconstriction tone by 2.8 Ϯ 0.9% while 10 Ϫ4 M NaHS decreased preconstriction tone by 10.0 Ϯ 7.5% (P ϭ ns compared with NaHS 10 Ϫ5 M). 10 Ϫ3 M NaHS further decreased tone to 76.9 Ϯ 12.9% of preconstriction tone (P ϭ 0.001 compared with NaHS 10 Ϫ4 M). In endothelial-denuded coronary arteries, NaHS also had little vasoconstrictive effect at 10 Ϫ5 M and 10 Ϫ4 M and induced vasodilation at 10 Ϫ3 M: 10 Ϫ3 M NaHS reduced preconstriction tone by 76.5 Ϯ 7.9% in denuded vessels compared with 218.5 Ϯ 52.0% increase in tone in endothelial-intact vessels (P ϭ 0.00081).
Representative traces of 3-MP dose responses are shown in Fig. 5 for untreated (Fig. 5A ) and with OBAA incubation (Fig.  5B) , L-NAME incubation (Fig. 5C) , and endothelial denuding (Fig. 5D ). Representative trace of pyruvate dose response is shown in Fig. 5E . Representative traces of NaHS dose responses are shown in Fig. 6 for untreated (Fig. 6A) , with OBAA incubation (Fig. 6B) , L-NAME incubation (Fig. 6C) , and endothelial denuding (Fig. 6D) .
NO-H 2 S interaction. Since enhanced preconstriction tone could be explained by decreased NO bioavailability, we tested whether H 2 S had a direct effect on NOS activity and NO production. Maximum endothelial-mediated vasorelax- Fig. 2 . In vitro amperometric measurement of tissue H2S production. Michaelis-Menten kinetics of MPST (A) and CSE (B) were characterized in rat liver homogenate. For coronary H2S production, rat coronary homogenate was incubated with 1 mM -mercaptopyruvate (3-MP) to measure MPST-mediated H2S production or with 50 mM L-cysteine to measure CSEmediated H2S production (C). For cellular H2S production, lysates of HCAEC were incubated with 3-MP (1 mM) to measure MPST-mediated H2S production or L-cysteine (50 mM) to measure CSE-mediated H2S production (D). Statistical significance was evaluated by Students' t-test (*P Ͻ 0.05; **P Ͻ 0.01). Fig. 3 . In vivo coronary vasorelaxation in CSE knockout and pharmacologically-inhibited mice. Coronary vasorelaxation function was evaluated in vivo by measuring increase in flow velocity using high-resolution ultrasound. Dose-dependent increases in flow velocity to ATP (A), representing agonist-induced vasorelaxation, and dobutamine (B), representing metabolic demand-induced vasorelaxation, were obtained. CSE activity was inhibited by intravenous administration of 50 mg/kg propargylglycine (PPG) 30 min before flow velocity measurement. ATP-induced vasorelaxation response was not different among wild-type (WT), PPG-treated wild-type, and CSE knockout mice (A). Vasorelaxation response to dobutamine-induced increase in cardiac metabolic demand was also not different between cohorts (B). ation with 10 Ϫ5 M ACh was not different between vessels preconstricted only with U46619 and vessels that exhibited increased preconstriction tension from the addition of 10
Ϫ3
M NaHS or 10
Ϫ4 M 3-MP (Fig. 7A) . ACh-induced vasorelaxation was 86.0 Ϯ 2.4% for U46619 only preconstricted vessels compared with 81.0 Ϯ 7.2% relaxation for vessels with enhanced preconstriction tone from NaHS and 72.7 Ϯ 8.6% relaxation for vessels with increased preconstriction tone from 3-MP. ACh-induced vasorelaxation was also significantly reduced with L-NAME incubation compared with untreated vessels: vasorelaxation was 20 Ϯ 5% with L-NAME incubation compared with 86.0 Ϯ 2.4% in untreated U46619 only vessels. We next tested whether NO could directly interact with H 2 S. Fluorescence intensity increased with increasing dose of NaHS, demonstrating that AzMC reacted with NaHS (Fig. 7B) . Increasing SNP concentration caused decreasing fluorescence intensity and therefore H 2 S availability (Fig. 7C) . In a complementary approach, the NO-H 2 S interaction was examined amperometrically. In these experiments, increasing doses of SNP as well as GSNO caused decreased H 2 S availability, while GSH did not affect H 2 S (Fig. 7D) . G -nitro-L-arginine methyle ester (L-NAME) incubation significantly reduced 3-MP-mediated vasoconstriction. Endothelial removal resulted in 3-MP-mediated vasodilation. Exogenous H2S donor NaHS also induced vasoconstriction in preconstricted arteries in a dose-dependent manner (B). OBAA incubation attenuated NaHS-induced vasoconstriction. L-NAME and endothelial denuding removed NaHS-induced vasoconstriction and only presented NaHS-induced vasodilation. #P Ͻ 0.05 and ##P Ͻ 0.01, comparing between previous dose within the same treatment group; *P Ͻ 0.05 and **P Ͻ 0.01, when comparing treated groups with untreated within a dose. , 100 M L-NAME (C), and after endothelial denudation (D). Pyruvate (E) was used as a control for 3-MP.
DISCUSSION
We investigated the role of H 2 S and the contribution of vascular H 2 S producers CSE and MPST in coronary tone vasoregulation. The new findings of this study are as follows: 1) CSE is not a significant contributor to coronary vasoregulation; the data shown here provide evidence that supports the involvement of MPST in coronary vasoregulation; 2) in HCAECs and in rat and mouse coronary arteries, MPST is the predominant source of H 2 S; and 3) this study supports the role of H 2 S as a coronary vasoconstrictor when NO bioavailability is physiological and vasodilator in the absence of NO.
Protein abundance measurement by Western blot showed that CSE and MPST are expressed in human endothelial cells and rat and mouse vascular tissue, although the relative expression between vascular beds varies between the species. CSE expression was robust in the aorta compared with the coronary artery in rats and mice. In contrast, MPST expression was similar in the aorta and coronary in rats and MPST Fig. 6 . NaHS dose response traces. Representative vasotension traces of NaHS in untreated coronary artery (A), after OBAA incubation (B), after L-NAME incubation (C), and after endothelial denudation (D). Fig. 7 . H2S-mediated vasoconstriction via reduced endothelial nitric oxide synthase (eNOS) activity and decreased nitric oxide (NO) bioavailability. eNOS activity was measured by percent relaxation with addition of 10 Ϫ5 M acetylcholine (ACh) bolus after maximum increase in preconstriction tension induced by NaHS, 3-MP, or L-NAME (A). ACh relaxation response was compared with vessels preconstricted with U46619 only. Maximum ACh-induced endothelialmediated relaxation was not different among U46619 only and NaHS or 3-MP constricted vessels; L-NAME significantly attenuated ACh-induced relaxation. Statistical significance was evaluated with 1-way ANOVA, followed by Tukey's post hoc analysis (***P Ͻ 0.001). H2S effect on NO bioavailability was measured in vitro by fluorometric probe 7-azido methylcoumarin (AzMC). Fluorescence intensity of AzCM increased with H2S dose (B). Addition of increasing dose of NO donor sodium nitroprusside (SNP) to 10 Ϫ3 M NaHS resulted in a dose-dependent decrease in fluorescence intensity (C). H2S-NO interaction was monitored amperometrically. Addition of increasing doses of the NO donors S-nitrosoglutathione (GSNO) or SNP resulted in a dose-dependent decrease in H2S in the headspace of an air-tight vial as measured amperometrically. Glutathione (GSH) did not affect H2S concentration (D).
expression was much higher in the mouse coronary artery compared with the aorta. The differences in the relative abundance of the proteins in the conduit arteries and arterioles could be due to the distinct properties and functions of these vessels. Conduit vessels are highly compliant and offer little resistance to flow. The arterioles on the other hand are resistance vessels and regulate organ perfusion and blood pressure by vasoconstriction and relaxation in response to various stimuli. The presence of H 2 S-producing enzymes can provide an alternative pathway to NO-dependent vasoregulation and thus organ perfusion in conditions where NO bioavailability is compromised.
Alternatively, these differences could be due to differences in vascular health. CSE and MPST expression have been shown to be influenced by pathological conditions. In a mouse heart failure model, mice with heart failure induced by thoracic aortic constriction had elevated CSE expression and reduced MPST expression in the cardiac tissue (13) . While the rats from which the tissue was harvested can be considered healthy, we did not ascertain the vascular health status of the donors of the human cell lines. Nevertheless, the expression data demonstrate that MPST is expressed in the coronary artery and support the possibility of endogenous H 2 S production in the coronary vasculature.
The Michaelis-Menten kinetics of CSE and MPST were examined in vitro using rat liver homogenate. For 3-MP, the K m value was 0.46 Ϯ 0.14 mM 3-MP. For CSE, the K m value was 21.38 Ϯ 4.31 mM L-cysteine, a concentration far exceeding physiologically relevant L-cysteine values. The previously reported K m value is 1.2 Ϯ 0.1 mM 3-MP for wild-type rat liver-derived MPST (19) , which is comparable to our findings. On the other hand, for CSE the previously reported K m value is 1.9 mM L-cysteine for wild-type human CSE (9) . Differences in reported values can be attributed to the use of a liver homogenate in our study compared with purified enzyme preparations in previous studies. In the homogenate, other proteins may compete for both PLP cofactor and L-cysteine substrate, markedly shifting the observed K m for CSE. Moreover, in the previous studies, both reactions were performed at basic pH, pH 9.55 for the MPST reaction and pH 8.2 for the CSE reaction. The reactions in this study were performed at pH 7.4, which is also the pH at which the vasoreactivity studies were performed. The difference in reaction pH may also account for the discrepancy in the observed K m value. The K m value of human CSE for L-cysteine has also been shown to vary significantly with polymorphic variants (31) .
In vitro amperometric H 2 S measurement in rat coronary artery homogenate and HCAEC lysates showed that H 2 S produced through the MPST pathway was significantly greater than through the CSE pathway. These reactions were performed at 2-mM 3-MP or 50-mM L-cysteine, concentrations greater than twofold the observed K m value in this study, to ensure maximal (specific) activity of the enzymes. The higher expression of the 3-MPST in the coronary artery coincides with higher rates of 3-MP-dependent H 2 S production in coronary artery homogenates, further supporting the idea that 3-MPST is the primary source of H 2 S in the coronary vasculature.
The in vivo coronary vasorelaxation responses in CSEdeficient and CSE-inhibited mice were not different from untreated wild-type mice. In conjunction with the lack of CSE-mediated H 2 S production in vitro, these in vivo data further support the notion that CSE-derived H 2 S does not significantly contribute to coronary vasoregulation. Our findings are confirmed by previous studies that reported lack of coronary vasodilation upon addition of L-cysteine, suggesting minimal involvement of CSE in coronary tone modulation (4, 6) . The insignificant role of CSE-produced H 2 S in the coronary vasculature seems counterintuitive given the significant role of CSE-produced H 2 S in regulating tone of the resistance arteries (29) . However, endothelial protein expression and associated phenotypic traits have been shown to vary by vascular bed. For instance, in the heart, endocardial endothelial cells express connexin (CX) 43, CX40, and CX37 while myocardial capillary endothelial cells do not, consistent with the observation that endocardial endothelial cells possess a larger number of gap junctions than myocardial endothelial cells (1) . It is therefore not unreasonable that the coronary arteries, which are controlled locally, have different main vasoactive mediators than the resistance arteries, which are controlled neurohumorally.
We demonstrated in vitro that the coronary artery can produce H 2 S by the MPST pathway. Because direct MPST inhibitors are currently unavailable and transgenic deletion model was not readily accessible, we determined if MPST was important physiologically using ex vivo wire myography. The vasoactive response to MPST substrate 3-MP was similar to the vasoactive response to H 2 S donor NaHS. There was no response to pyruvate, suggesting that the effects of 3-MP are due to H 2 S synthesis rather than pyruvate. The vasoconstrictive effects were not significantly altered with PLA2 inhibition but disappeared with NOS inhibition and endothelial denudation. These data support that the effects of 3-MP are mediated through MPST production of H 2 S as opposed to direct vascular effects of 3-MP. Although 3-MP-induced vasoconstriction was removed by L-NAME incubation and endothelial removal, 3-MP was not observed to induce vasodilation to the same degree as NaHS. Lack of vasodilatory effects of 3-MP could be due to insufficient substrate amount to produce the amount of H 2 S necessary for vasodilation. Coronary vasodilation was observed in this study and has been previously reported to occur at 1-mM NaHS. This concentration of H 2 S may not have been possible to produce in the tissue with the 3-MP concentration used.
Interestingly, we observed the vasoconstrictive effects of NaHS in untreated coronary arteries, which contradicts previous studies that reported vasodilatory effects of NaHS (4, 5, 6, 8) . We demonstrated, however, that the vasoconstrictive effect of NaHS is eNOS and therefore NO dependent. NOS inhibition with L-NAME yielded no vasoconstriction and only vasodilation. A similar response observed with endothelial denuding identified the involvement of eNOS and eNOS-derived NO. Such NO dependence has also been observed in CO-mediated vasoactivity, where NO plays a "permissive" role in COinduced dilatation in arteries (15) .
Reducing NO bioavailability through eNOS inhibition has been shown to further increase preconstriction tension (18) . The enhanced vasoconstriction with addition of NaHS observed in this study could therefore occur through eNOS inhibition or NO scavenging. Both H 2 S interference with eNOS activity as well as H 2 S reaction with NO have been previously described. H 2 S was shown to cause a dose-dependent decrease in activity of recombinant bovine eNOS. The resulting reduction in NO bioavailability was associated with the observed vasoconstrictive effects of NaHS in rat and mouse aorta (14) . Aortic vasoconstriction observed at low NaHS doses was attributed to the vasoconstrictive effects of reduced NO bioavailability overriding the vasodilatory effects of H 2 S. Aortic vasodilation observed at high NaHS doses was attributed to the vasodilatory effects of H 2 S overriding the vasoconstrictive effects of decreased NO bioavailability. The reported H 2 S inhibition of eNOS appears to contradict other studies that demonstrated that exogenous H 2 S promoted eNOS function and eNOS production of NO (12), (2) . However, the duration of the exogenous H 2 S administration was different between the studies. H 2 S donor treatment was chronic in the studies showing cooperative effects of H 2 S on eNOS function and acute in the study that showed dose-dependent decrease in eNOS activity as well as this study. H 2 S has also been shown to react with NO to form HNO or a nitrosothiol, demonstrating the scavenging effect of H 2 S. Mixing NaHS with SNP reduced the vasodilatory effects of SNP in preconstricted rat aortic rings, further supporting that H 2 S reacted with NO and reduced NO bioavailability through scavenging (2, 25) .
Our ex vivo vasoreactivity data showed that endothelialmediated relaxation was maximal after NaHS-induced vasoconstriction. NOS inhibition with L-NAME significantly attenuated endothelial-mediated relaxation. In addition, 10 Ϫ5 M ACh consistently induced complete relaxation between ring sections and animals for both NaHS and 3-MP, supporting that eNOS activity was truly unimpaired. These ex vivo vasoreactivity data therefore support that H 2 S-induced vasoconstriction is not through inhibition of eNOS activity.
Our fluorometric data demonstrated the scavenging interaction of H 2 S and NO. Whether the reaction product of H 2 S and NO is also a vasoconstrictor was not tested in this study. However, as noted earlier, this reaction product was shown previously to not have vasoactive effects (2, 25) . Vasoconstriction observed in this study can therefore be attributed directly to decreased NO bioavailability. Because only the vasodilatory effects of NaHS were observed in the absence of NO, either by L-NAME inhibition or by endothelial denuding, we agree that H 2 S can act a vasodilator in the coronary vasculature. We further conclude that its vasoconstrictive effects are due to its scavenging interaction with NO. The NO dependency of the vasoactive effects of H 2 S suggests a change in role from regulatory to vasodilatory with development of coronary artery disease. Under healthy conditions with physiological NO bioavailability, H 2 S appears to primarily regulate NO. In disease conditions with diminished NO bioavailability, H 2 S could serve as a compensatory vasomediator. By extension, these findings support that exogenous H 2 S induces vasoconstriction in healthy coronary arteries and vasodilation in diseased coronary arteries. Therapies involving administration of exogenous H 2 S would therefore benefit coronary artery disease patients but would be counterproductive as a supplement for patients with healthy coronary arteries.
Limitations of this study. The absence of H 2 S measurement in the bath during the wire myograph experiments to confirm that the effects of 3-MP are due to MPST-mediated H 2 S production is a limitation of this study. This detection was limited by the sensitivity of the amperometric probe in a noisy environment. Nevertheless, similar effects and mechanism of action between 3-MP and NaHS support the conclusion that 3-MP is acting on the coronary artery through H 2 S production by MPST. In vivo H 2 S concentrations are estimated to range from nanomolar to low micromolar levels. Thus the concentrations of exogenous H 2 S from NaHS used in the vasoreactivity experiments in this study are supraphysiological. While micromolar to millimolar concentrations of 3-MP were used in the bath, it is unclear how much intracellular H 2 S this translates to. Thus, the responses described are more likely to be relevant during sulfide-based therapies.
GRANTS
This work was supported by National Heart, Lung, and Blood Institute Grant 1R01-HL-105296-01.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s). 
AUTHOR CONTRIBUTIONS
